Voyager Therapeutics, Inc.
VYGR
$4.46
-$0.42-8.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -84.18% | -589.88% | -1,296.21% | -2,682.29% | -149.12% |
| Total Depreciation and Amortization | -14.18% | -20.44% | -13.27% | -0.28% | 6.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.47% | 26.97% | 30.36% | 101.41% | 90.77% |
| Change in Net Operating Assets | -211.14% | 85.43% | 42.73% | -1,380.40% | 145.47% |
| Cash from Operations | -765.23% | -375.67% | -544.88% | -953.38% | -119.65% |
| Capital Expenditure | 26.27% | 48.43% | 53.15% | 58.31% | -8.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 240.18% | 244.25% | 131.86% | 117.97% | 34.00% |
| Cash from Investing | 232.24% | 224.49% | 130.47% | 116.81% | 33.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.28% | -98.90% | -98.96% | -98.92% | 238.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.28% | -98.90% | -98.96% | -98.92% | 238.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -261.34% | -233.22% | 80.71% | 44.85% | 112.79% |